Clinical trial
BIG 02/98 Docetaxel - Breast Cancer
NCT00174655 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00174655 |
|---|---|
| Title | BIG 02/98 Docetaxel - Breast Cancer |
| Official title | An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-positive Breast Cancer… |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Doxorubicine + docetaxel sequential, doxorubicine + cyclophosphamide sequential, doxorubicine + cyclophosphamide combined, doxorubicine + docetaxel combined |
| Enrollment | 2,887 |
| Start date | Jun 1, 1998 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 10, 2011 |
| Countries | Australia, Austria, Belgium, Brazil, Chile, Czechia, Denmark, Germany, Hungary, Ireland, Israel, Italy and 9 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: